THE BEST SIDE OF ABBV-744 CLINICAL TRIAL PHASE 1 RESULTS

The current work examined the potential of using ARV-825 and ABBV-744 to improve the effectiveness of tamoxifen or fulvestrant plus palbociclib. ARV-825 was effective in equally p53 wild-type (WT) breast tumor cells and in cells lacking useful p53 both by itself or in combination with tamoxifen, while the effectiveness of ABBV-744 was limited to fu